John Allan, MD

Articles by John Allan, MD

Head-to-Head Trials of BTKi in Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 1st 2023

Shared insight on and reactions to head-to-head comparison trials between novel BTK inhibitors in the setting of chronic lymphocytic leukemia.

BTK Inhibitors in Relapsed/Refractory Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

January 25th 2023

Switching focus to the second-line setting, expert hematologist-oncologists evaluate the continued role of BTK inhibitors in chronic lymphocytic leukemia.

Second Generation BTKi in CLL: First-Line Treatment With Acalabrutinib or Zanubrutinib

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

January 25th 2023

Centering discussion on second-generation BTK inhibitors, expert panelists review clinical data behind first-line acalabrutinib and zanubrutinib, respectively.

Chronic Lymphocytic Leukemia: Role of First-Generation BTK Inhibitors

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

January 18th 2023

A brief review of first-line BTK inhibition in chronic lymphocytic leukemia following the advent of ibrutinib, along with considerations for minimal residual disease testing in this setting.

Brief Overview of Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

January 18th 2023

Expert hematologist-oncologist Sonali Smith, MD, shares a brief overview of chronic lymphocytic leukemia (CLL), highlighting incidence, prognosis, and molecular subsets.

John N. Allan, MD, of Weill Cornell Medical College

Dr. Allan on the Safety Profile of Ibrutinib in High-Risk CLL

ByJohn Allan, MD

December 23rd 2020

John N. Allan, MD, discusses the safety profile of ibrutinib in high-risk chronic lymphocytic leukemia.

Dr. Allan on the Use of Vecabrutinib Therapy in B-Cell Malignancies

ByJohn Allan, MD

January 31st 2020

John N. Allan, MD, assistant attending physician at NewYork-Presbyterian Hospital and assistant professor of medicine, Weill Cornell Medical College, Cornell University, discusses the use of vecabrutinib (SNS-062) therapy in patients with B-cell malignancies.

John Allan, MD

Articles by John Allan, MD

Head-to-Head Trials of BTKi in Chronic Lymphocytic Leukemia

BTK Inhibitors in Relapsed/Refractory Chronic Lymphocytic Leukemia

Second Generation BTKi in CLL: First-Line Treatment With Acalabrutinib or Zanubrutinib

Chronic Lymphocytic Leukemia: Role of First-Generation BTK Inhibitors

Brief Overview of Chronic Lymphocytic Leukemia

Dr. Allan on the Safety Profile of Ibrutinib in High-Risk CLL

Dr. Allan on the Use of Vecabrutinib Therapy in B-Cell Malignancies

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies